Amylin Hit Hardest By Bydureon Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin Pharmaceuticals, Eli Lilly, and Alkermes, will all feel the financial effects of the diabetes drug's delay to different degrees.